Advancements in Immunotherapies With John DiPersio, MD, PhD

The latest episode of the ASTCT Talks episode features John DiPersio, MD, PhD, on emerging therapies in the treatment of acute myeloid leukemia.

This episode of ASTCT Talks features a recently recorded conversation with John DiPersio, MD, PhD, a Bone Marrow Transplant Specialist and Medical Oncologist at the Siteman Cancer Center at the Washington University School of Medicine, and a past president of ASTCT. We discuss emerging therapies to treat acute myeloid leukemia, advancements in immunotherapies, and much more.

Tune in.

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.

Related Videos
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.